- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Patent holdings for IPC class A61K 31/439
Total number of patents in this class: 2406
10-year publication summary
|
160
|
167
|
166
|
178
|
151
|
163
|
152
|
124
|
172
|
32
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Wockhardt Limited | 208 |
48 |
| Genzyme Corporation | 1325 |
45 |
| Lenz Therapeutics Operations, Inc. | 46 |
41 |
| Chiesi Farmaceutici S.p.A. | 961 |
31 |
| Novartis AG | 10494 |
29 |
| Merck Sharp & Dohme LLC | 3751 |
29 |
| AstraZeneca AB | 2833 |
28 |
| Bristol-myers Squibb Company | 4795 |
26 |
| Meiji Seika Pharma Co., Ltd. | 255 |
24 |
| Vertex Pharmaceuticals Incorporated | 1624 |
22 |
| Boehringer Ingelheim International GmbH | 4595 |
21 |
| Centre National de La Recherche Scientifique | 10801 |
17 |
| Theravance Biopharma R&D IP, LLC | 442 |
17 |
| The Scripps Research Institute | 1343 |
16 |
| Glaxo Group Limited | 4207 |
15 |
| Astellas Pharma Inc. | 1050 |
15 |
| Oyster Point Pharma, Inc. | 76 |
14 |
| Skyhawk Therapeutics, Inc. | 135 |
14 |
| Gilead Sciences, Inc. | 2134 |
13 |
| F. Hoffmann-La Roche AG | 7893 |
12 |
| Other owners | 1929 |